AlphaCrest Capital Management’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-33,472
Closed -$3.19M 292
2022
Q3
$3.19M Sell
33,472
-76,498
-70% -$7.57M 0.19% 82
2022
Q2
$10.2M Sell
109,970
-46,654
-30% -$4.55M 0.49% 13
2022
Q1
$15.9M Buy
156,624
+97,532
+165% +$10.2M 0.89% 3
2021
Q4
$6.1M Buy
59,092
+33,564
+131% +$3.1M 0.23% 69
2021
Q3
$2.17M Sell
25,528
-61,860
-71% -$5.18M 0.11% 270
2021
Q2
$7.29M Sell
87,388
-54,300
-38% -$4.45M 0.31% 47
2021
Q1
$10.7M Buy
141,688
+115,732
+446% +$8.43M 0.59% 13
2020
Q4
$1.77M Sell
25,956
-13,516
-34% -$879K 0.15% 166
2020
Q3
$2.31M Buy
39,472
+35,753
+961% +$2.22M 0.25% 69
2020
Q2
$242K Sell
3,719
-6,107
-62% -$385K 0.04% 736
2020
Q1
$583K Sell
9,826
-8,271
-46% -$552K 0.07% 494
2019
Q4
$1.34M Sell
18,097
-36,607
-67% -$2.57M 0.11% 223
2019
Q3
$3.45M Buy
54,704
+5,844
+12% +$346K 0.21% 81
2019
Q2
$2.66M Sell
48,860
-16,295
-25% -$878K 0.23% 92
2019
Q1
$3.51M Buy
65,155
+40,044
+159% +$2.47M 0.53% 15
2018
Q4
$1.65M Buy
+25,111
New +$1.87M 0.49% 15

Other funds holding CVS

AlphaCrest Capital Management's CVS Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of CVS Health (CVS) in Q4 2022, closing a stake of 33,472 shares — an estimated $3.19M sold.

AlphaCrest Capital Management first reported a position in CVS in Q4 2018 and held it in 16 quarters. The position peaked at $15.9M in Q1 2022. 2,405 funds tracked by Wall St. Rank hold CVS as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining CVS Health position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 33,472 CVS Health shares in Q4 2022, an estimated $3.19M.
  • AlphaCrest Capital Management first reported a position in CVS Health in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's CVS Health position peaked at $15.9M in Q1 2022.
  • 2,405 funds tracked by Wall St. Rank held CVS Health as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.